James R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center

New name, logo, and business unit alignment introduced as part of an extensive rebranding initiative…

read more

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Results from the I-RUX Study Published in ASH2020

January 19, 2021 WEST HOLLYWOOD, CA, January 19, 2021 – ONCOtherapeutics and Dr. James Berenson…

read more

Serum BCMA to Determine Disease Progression in RRMM Patients

Serum BCMA to Determine Disease Progression in RRMM Patients Sponsor: Incyte Protocol Number: I-RUX-19-52 Start…

read more

A Pilot Study Examining Selinexor’s Ability to Overcome Resistance in Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy

A Pilot Study Examining Selinexor’s Ability to Overcome Resistance in Multiple Myeloma Patients Who Are…

read more

A Randomized Phase 2 Study of Peri-Operative Ipilimumab, Nivolumab and Cryoablation Versus Standard Peri-Operative Care in Women

A Randomized Phase 2 Study of Peri-Operative Ipilimumab, Nivolumab and Cryoablation Versus Standard Peri-Operative Care…

read more

Neoadjuvant Her2-targeted Therapy and Immunotherapy with Pembrolizumab

Neoadjuvant Her2-targeted Therapy and Immunotherapy with Pembrolizumab Sponsor: Merck/Cedars-Sinai Protocol Number: 2018-04-McArthur-neoHP Start Date: 11/15/2019…

read more

A Phase 2 Study of Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

 A Phase 2 Study of Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to…

read more

A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone

A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide,…

read more

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients Sponsor: Incyte Protocol…

read more

A Phase 2 Study of Pomalidomide as a Replacement for Lenalidomide for Multiple Myeloma Patients

A Phase 2 Study of Pomalidomide as a Replacement for Lenalidomide for Multiple Myeloma Patients…

read more